State-of-the-Art Viral Vector Gene Therapy in Germany
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 22318
Special Issue Editors
Interests: hematology; oncology; virology; gene therapy; vector safety
Special Issue Information
Dear Colleagues,
Three decades after the first approved viral gene therapy clinical study, viral vectors are consolidated candidates for a wide range of therapeutic applications in clinical gene therapy, immunotherapy, and vaccination. R approvals of vector-based drugs have significantly boosted preclinical and clinical research in the field, providing the basis to understand and overcome the existing hurdles for effective and safe viral gene therapy products.
Since its early contribution to pioneering gammaretroviral clinical gene therapy studies, Germany has been actively participating in this evolution, and this Special Issue of Viruses aims to provide an overview of viral gene therapy and its state-of-the-art within the country. We cordially invite you to contribute reviews or original research articles giving insights into any step of the roadmap from basic research to preclinical and clinical studies, advances in viral and gene editing technologies, safety considerations, as well as awareness of the current regulatory framework.
Dr. Manfred Schmidt
Dr. Irene Gil-Farina
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viral vectors
- in vivo gene therapy
- ex vivo gene therapy
- immunotherapy
- oncolytic viral vectors
- viral vector immunogenicity
- genotoxicity
- gene therapy efficacy
- viral vector manufacturing
- regulatory aspects
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.